| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000007925 |
| Receipt No. | R000009306 |
| Official scientific title of the study | Examination of the usefulness as the tumor marker of the NY-ESO-1 antibody titer in the stomach cancer patient |
| Date of disclosure of the study information | 2012/05/21 |
| Last modified on | 2018/05/17 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Examination of the usefulness as the tumor marker of the NY-ESO-1 antibody titer in the stomach cancer patient | |
| Title of the study (Brief title) | Examination of the usefulness as the tumor marker of the NY-ESO-1 antibody titer in the stomach cancer patient | |
| Region |
|
|
| Condition | |||
| Condition | gastric cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | Analyze usefulness as the tumor marker of the NY-ESO-1 antibody titer of the stomach cancer patient. |
| Basic objectives2 | Bio-availability |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | Recurrence prediction by the NY-ESO-1 antibody titer
In the stomach cancer patients, with NY-ESO-1 antibody titer positive before surgery, that has been resected radically, NY-ESO-1 antibody titer was measured. We examine The recurrence rate of the NY-ESO-1 antibody-positive case of the first year after surgery. |
| Key secondary outcomes | 1. NY-ESO-1 antibody titer positive rate
2. Incidence of the NY-ESO-1 antigen expression in the gastric cancer tissue 3. Correlation between NY-ESO-1 antibody titer and prognosis 4. Correlation between expression of the NY-ESO-1 antigen and prognosis 5. Relations withNY-ESO-1 antibody titer and the effect of the chemotherapy |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who are diagnosed as gastric cancer which are proven by biopsy as adenocarinoma and can receive radical resection. | |||
| Key exclusion criteria | Synchronous or metachronous (within 5 years) malignancies | |||
| Target sample size | 1000 | |||
| Research contact person | |
| Name of lead principal investigator | Yuichiro Doki |
| Organization | Osaka University,Graduate School of Medicine |
| Division name | Department of Gastroenterological Surgery |
| Address | 2-2 Yamadaoka, Suita city, Osaka, Japan |
| TEL | 06-6879-3251 |
| ktanaka@gesurg.med.osaka-u.ac.jp | |
| Public contact | |
| Name of contact person | Koji Tanaka |
| Organization | Osaka University Clinical Research Group for Gastroenterological Study |
| Division name | Osaka University Clinical Research Group for Gastroenterological Study |
| Address | 2-2 Yamadaoka, Suita city, Osaka, Japan |
| TEL | 06-6879-3251 |
| Homepage URL | |
| ktanaka@gesurg.med.osaka-u.ac.jp | |
| Sponsor | |
| Institute | Osaka University Clinical Research Group for Gastroenterological Study |
| Institute | |
| Department | |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | not yet |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000009306 |